The Food and Drug Administration yesterday posted updated comparative performance data for molecular tests to diagnose the COVID-19 virus.

Test developers, in order to receive emergency use authorization, are required to assess their test’s performance against a reference panel of viral samples.

In FDA’s data, a lower product LoD (limit of detection) indicates a test’s ability to detect a smaller amount of viral material in a given sample, signaling a more sensitive test. FDA updates the data as it receives additional results to help inform laboratories, health care providers and patients about the relative performance of available tests.

Related News Articles

Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…
Headline
The Centers for Medicare & Medicaid Services yesterday issued a final rule updating the home health prospective payment system for calendar year 2021.…
Headline
The Federal Reserve Board today reduced the minimum loan size for three Main Street Lending Program facilities from $250,000 to $100,000 and adjusted…
Headline
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New…
Headline
The Food and Drug Administration Wednesday updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient…
Headline
Over 10,000 eligible nursing homes, or 76% of the field, will receive a portion of $333 million in COVID-19 Provider Relief Funds for meeting infection control…